Kedrion SpA   Report issue

For profit Phase 1 Phase 3
Founded: Fort Lee NJ United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2012
NCT01531803
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Humán Bioplazma Kft - Kedrion | Kedrion Biopharma Inc. | Kedrion SpA | Kedrion S.p.A. | Kedrion, S.p.A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agammaglobulinemia (Phase 3)

Conjunctivitis (Phase 3)

Hypovolemia (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Rabies (Phase 3)

Skin Diseases, Genetic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 5